Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
Rheumatol Ther 2024 Epub ahead of print doi: 10.1007/s40744-024-00695-w
Patients classified as having a high neutrophil-to-lymphocyte ratio (NLR-High) who received filgotinib 200mg + MTX/csDMARDs exhibited consistently better responses after 12 weeks across clinical trials, clinical endpoints, and PROs, compared with NLR-Low patients. Taylor et al. analysed data from the 3 FINCH trials to investigate the potential association of baseline NLR with improved clinical response to filgotinib in MTX-naïve or MTX-experienced RA populations.
More consistent improvements in NLR-High patients were observed for filgotinib 200mg versus filgotinib 100mg. Improvements were less prominent in those who received adalimumab + MTX compared with those receiving filgotinib. These trends were most prominent among the MTX-IR population.
